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Rapid near patient testing for both current and past infections is urgently 
required 
“Test, test, test” is the key to controlling the spread of SARS-CoV-2 and its clinical 
manifestation, covid-19, according to the World Health Organisation.1 However, three 
months after notification of the novel coronavirus infection in China, there is 
inadequate access to appropriate diagnostic tests globally and confusion among 
healthcare professionals and the public about prioritisation of testing and 
interpretation of results. 
The virus is spread by the respiratory route, primarily by droplets and contact with 
contaminated surfaces and fomites, and by aerosol formation during invasive 
respiratory procedures. Virus is also found in urine, faeces, and 
saliva.2345 Asymptomatic shedding seems to be common, especially in children, and 
can spread infection.67 
The incubation period from infection to first symptom is typically 5 to 7 days, with a 
range of 4-14 days. Diagnosis of current infection relies on tests to detect virus in 
various body fluids. Antibody tests on blood are used to confirm past infection and 
presumed immunity to repeat infection, although duration and effectiveness of such 
protection are not yet known. 
Swab tests 
Respiratory shedding of virus peaks at the end of the first week after infection, just before 
and as symptoms are developing. It may be intermittent, so a single negative swab result can 
be misleading and tests may need to be repeated.123 Swabs must be taken correctly and 
transported in viral transport medium.8 
Nasopharyngeal swabs are more sensitive than oropharyngeal swabs and are best taken when 
symptoms first emerge.34589 Swabs from both sites are often combined to increase sensitivity. 
Deeper respiratory secretions such as sputum and bronchoalveolar fluid contain more virus, 
and yields increase over 2-3 weeks in more severe cases.34510 Faecal virus shedding can 
persist after resolution of diarrhoea. 
The gold standard test for diagnosis is detection of viral RNA by molecular methods, 
typically a reverse transcription polymerase chain reaction (RT-PCR). Test protocols require 
substantial equipment, reagents, and expertise and are often carried out in central or regional 
laboratories, especially in resource poor settings. Delays in transporting samples to the 
laboratory and returning results to the originator mean that overall test turnaround often 
exceeds 48 hours. Decentralisation of laboratories helps reduce these delays, but validated 
rapid near-patient tests are urgently needed to provide more timely information for both 
diagnosis and public health interventions.11 
Novel systems are being assessed for faster detection of key viral sequences51112 and a variety 
of point-of-care antigen detection devices have been developed, but their performance varies 
widely. Some antigen detection devices have poor sensitivity, meaning that infections are 
missed and infectious individuals are not managed appropriately.11 
Antibody tests 
Antibody tests are primarily used to determine if a person has already had covid-19. Specific 
IgM and IgG antibodies should start to become detectable after 4-5 days, with positive IgM 
antibodies in 70% of symptomatic patients by days 8-14 and 90% of total antibody tests 
positive by days 11-24. IgG reactivity is thought to reach >98% after several more weeks, but 
duration of this antibody response is not yet known.31314 
Antibodies can be detected by conventional ELISA tests or with near-patient lateral flow 
devices, similar to those used for pregnancy testing. These can deliver results in less than 20 
minutes from a few drops of blood obtained by finger prick. They usually combine tests for 
IgM and IgG and may not become positive until the second week of infection and sensitivity 
may be lower after asymptomatic infection.1415 Antibody detection tests may also be limited 
by poor specificity, so people are wrongly identified as having been infected and have a false 
sense of security.14 
Who should be tested? In countries such as Singapore and South Korea, aggressive 
programmes of testing, contact tracing, and isolation have contributed to early control of 
infection. As the epidemic progresses, the focus is on symptomatic patients and key workers 
and their families. Testing symptomatic patients for current infection when they attend 
healthcare facilities can inform contact tracing and infection prevention and control, 
particularly in the triage of patients to appropriate wards in hospital. Key workers, especially 
those in healthcare, may be self-isolating for long periods if a household member has 
symptoms. Exclusion of infection in the household enables staff to return to work, as would 
proof of staff immunity. 
Game changer 
Wide availability of testing for antibodies would be a game changer. Many healthcare staff 
are likely to have already been infected in the community or at work. Identification of 
resolved past infection could allow these people to return to work, on the assumption that past 
infection confers some level of immunity. Contacts of people who are currently infected 
could have antibody tests to find out whether they were still at risk. 
As antibody testing becomes more widely available throughout the community, a clearer 
picture should emerge of the proportion of infections that are asymptomatic and the true 
morbidity of covid-19.1161718 
In summary, interpretation of tests depends on the biological site and timing of samples, and 
recognition of both intermittent viral shedding and variation in the sensitivity and specificity 
of different test systems. New tests must be properly validated before use in any given 
setting, as “an unreliable test is worse than no test.”19 However, tests cannot be interpreted if 
they are not available—and that is the major challenge currently facing many countries, 
including the UK. 
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